The FDA proposed a streamlined approach for first-in-human (FIH) studies by considering a new “clinical trial notification pathway.” Under the concept, sponsors with validated preclinical data and existing pharmacology/toxicology packages could use an alternative to traditional investigational new drug review processes. The proposal is intended to reduce time and duplicative requirements while maintaining safety and ethical standards, particularly for smaller biotech firms. The FDA’s $7.2 billion budget request for 2027 includes details of the approach and points to comparative faster approval mechanisms used internationally. If adopted, the policy could change the operational timeline for early drug discovery pipelines and alter where sponsors allocate resources for Phase 1 readiness.